1Department of Pharmaceutics, Ali Allana College of Pharmacy, Akkalkuwa, Maharashtra
2Department of Pharmacology, Ahinsa Institute of Pharmacy, Dondaicha, Dist-Dhule, Maharashtra
Cancer is leading cause of death worldwide, accounting for an estimated 9.6 million deaths in 2018. Breast cancer 2.09 million death in 2018. Approximately 70% of deaths from cancer occurs in low-and middle-income countries. Human epidermal growth factor receptor (HER) 2 is overexpressed in 20–25% of breast cancer and has historically been poor prognostics marker. Niratinib maleate is an anti breast cancer drug.it is crystalline form and chemically (2E)-N-[4-[[3-chloro-4-[(pyridin-2-yl) methoxy] phenyl] amino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino) but-2-enamide maleate. It an oral, irreversible pan-Erb B receptor tyrosine kinase inhibitor and it can effectively inhibit the activity of Erb B1, ErbB2 tyrosine kinase.
Breast cancer, tyrosine kinase, Niratinib maleate, HER (Human epidermal growth factor receptor)
